Use of the human cytomegalovirus (HCMV) antigenemia assay for diagnosis and monitoring of HCMV infections and detection of antiviral drug resistance in the immunocompromised

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background: Quantification of viral load in blood has proven to be helpful in the follow-up of disseminated HCMV infections in immunocompromised patients. Objectives: (i) To describe the antigenemia assay and its optimization and (ii) to analyze the use of the antigenemia assay for the diagnosis and monitoring of HCMV infections and for the detection of treatment failures. Study design: This article is intended to give an overview of our experience in the use of the antigenemia assay. Results and conclusions: In solid organ transplant recipients and patients with AIDS, HCMV symptomatic infections mostly appear when antigenemia values are > 300 pp65-positive PBL/2 x l05 examined. To avoid the appearance of overt HCMV disease antiviral treatment could be administered when antigenemia levels are > 100 pp65-positive PBL/2 x l05 examined. Bone marrow transplant recipients show symptomatic HCMV infections when antigenemia values are > 100 pp65- positive PBL/2 x 105 examined. This group of patients should be treated when antigenemia levels are <10 pp65-positive PBL/2 x 105 examined due to the higher mortality rate associated with HCMV complications. A decrease in antigenemia levels during therapy indicates a good response to antiviral drug, while stable or increasing values document a treatment failure and the emergence of drug-resistant HCMV strains.

Original languageEnglish
Pages (from-to)51-60
Number of pages10
JournalJournal of Clinical Virology
Volume11
Issue number1
DOIs
Publication statusPublished - Jul 24 1998

Fingerprint

Viral Drug Resistance
Cytomegalovirus Infections
Cytomegalovirus
Treatment Failure
Antiviral Agents
Immunocompromised Host
Viral Load
Acquired Immunodeficiency Syndrome
Bone Marrow
Transplants
Mortality

Keywords

  • Antigenemia
  • Antiviral treatment
  • Drug resistance
  • Human cytomegalovirus (HCMV)
  • Viral load

ASJC Scopus subject areas

  • Applied Microbiology and Biotechnology
  • Virology
  • Immunology and Allergy
  • Infectious Diseases

Cite this

@article{171426450b7342599ad7d8eb73e4b102,
title = "Use of the human cytomegalovirus (HCMV) antigenemia assay for diagnosis and monitoring of HCMV infections and detection of antiviral drug resistance in the immunocompromised",
abstract = "Background: Quantification of viral load in blood has proven to be helpful in the follow-up of disseminated HCMV infections in immunocompromised patients. Objectives: (i) To describe the antigenemia assay and its optimization and (ii) to analyze the use of the antigenemia assay for the diagnosis and monitoring of HCMV infections and for the detection of treatment failures. Study design: This article is intended to give an overview of our experience in the use of the antigenemia assay. Results and conclusions: In solid organ transplant recipients and patients with AIDS, HCMV symptomatic infections mostly appear when antigenemia values are > 300 pp65-positive PBL/2 x l05 examined. To avoid the appearance of overt HCMV disease antiviral treatment could be administered when antigenemia levels are > 100 pp65-positive PBL/2 x l05 examined. Bone marrow transplant recipients show symptomatic HCMV infections when antigenemia values are > 100 pp65- positive PBL/2 x 105 examined. This group of patients should be treated when antigenemia levels are <10 pp65-positive PBL/2 x 105 examined due to the higher mortality rate associated with HCMV complications. A decrease in antigenemia levels during therapy indicates a good response to antiviral drug, while stable or increasing values document a treatment failure and the emergence of drug-resistant HCMV strains.",
keywords = "Antigenemia, Antiviral treatment, Drug resistance, Human cytomegalovirus (HCMV), Viral load",
author = "Fausto Baldanti and {Grazia Revello}, M. and Elena Percivalle and Giuseppe Gerna",
year = "1998",
month = "7",
day = "24",
doi = "10.1016/S0928-0197(98)00040-3",
language = "English",
volume = "11",
pages = "51--60",
journal = "Journal of Clinical Virology",
issn = "1386-6532",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Use of the human cytomegalovirus (HCMV) antigenemia assay for diagnosis and monitoring of HCMV infections and detection of antiviral drug resistance in the immunocompromised

AU - Baldanti, Fausto

AU - Grazia Revello, M.

AU - Percivalle, Elena

AU - Gerna, Giuseppe

PY - 1998/7/24

Y1 - 1998/7/24

N2 - Background: Quantification of viral load in blood has proven to be helpful in the follow-up of disseminated HCMV infections in immunocompromised patients. Objectives: (i) To describe the antigenemia assay and its optimization and (ii) to analyze the use of the antigenemia assay for the diagnosis and monitoring of HCMV infections and for the detection of treatment failures. Study design: This article is intended to give an overview of our experience in the use of the antigenemia assay. Results and conclusions: In solid organ transplant recipients and patients with AIDS, HCMV symptomatic infections mostly appear when antigenemia values are > 300 pp65-positive PBL/2 x l05 examined. To avoid the appearance of overt HCMV disease antiviral treatment could be administered when antigenemia levels are > 100 pp65-positive PBL/2 x l05 examined. Bone marrow transplant recipients show symptomatic HCMV infections when antigenemia values are > 100 pp65- positive PBL/2 x 105 examined. This group of patients should be treated when antigenemia levels are <10 pp65-positive PBL/2 x 105 examined due to the higher mortality rate associated with HCMV complications. A decrease in antigenemia levels during therapy indicates a good response to antiviral drug, while stable or increasing values document a treatment failure and the emergence of drug-resistant HCMV strains.

AB - Background: Quantification of viral load in blood has proven to be helpful in the follow-up of disseminated HCMV infections in immunocompromised patients. Objectives: (i) To describe the antigenemia assay and its optimization and (ii) to analyze the use of the antigenemia assay for the diagnosis and monitoring of HCMV infections and for the detection of treatment failures. Study design: This article is intended to give an overview of our experience in the use of the antigenemia assay. Results and conclusions: In solid organ transplant recipients and patients with AIDS, HCMV symptomatic infections mostly appear when antigenemia values are > 300 pp65-positive PBL/2 x l05 examined. To avoid the appearance of overt HCMV disease antiviral treatment could be administered when antigenemia levels are > 100 pp65-positive PBL/2 x l05 examined. Bone marrow transplant recipients show symptomatic HCMV infections when antigenemia values are > 100 pp65- positive PBL/2 x 105 examined. This group of patients should be treated when antigenemia levels are <10 pp65-positive PBL/2 x 105 examined due to the higher mortality rate associated with HCMV complications. A decrease in antigenemia levels during therapy indicates a good response to antiviral drug, while stable or increasing values document a treatment failure and the emergence of drug-resistant HCMV strains.

KW - Antigenemia

KW - Antiviral treatment

KW - Drug resistance

KW - Human cytomegalovirus (HCMV)

KW - Viral load

UR - http://www.scopus.com/inward/record.url?scp=0032563071&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032563071&partnerID=8YFLogxK

U2 - 10.1016/S0928-0197(98)00040-3

DO - 10.1016/S0928-0197(98)00040-3

M3 - Article

VL - 11

SP - 51

EP - 60

JO - Journal of Clinical Virology

JF - Journal of Clinical Virology

SN - 1386-6532

IS - 1

ER -